Abstract:Airway microbiota are known to contribute to lung diseases, such as cystic fibrosis (CF), but their contributions to pathogenesis are still unclear. To improve our understanding of host-microbe interactions, we have developed an integrated analytical and bioinformatic mass spectrometry (MS)-based metaproteomics workflow to analyze clinical bronchoalveolar lavage (BAL) samples from people with airway disease. Proteins from BAL cellular pellets were processed and pooled together in groups categorized by disease status (CF vs. non-CF) and bacterial diversity, based on previously performed small subunit rRNA sequencing data. Proteins from each pooled sample group were digested and subjected to liquid chromatography tandem mass spectrometry (MS/MS). MS/MS spectra were matched to human and bacterial peptide sequences leveraging a bioinformatic workflow using a metagenomics-guided protein sequence database and rigorous evaluation. Label-free quantification revealed differentially abundant human peptides from proteins with known roles in CF, like neutrophil elastase and collagenase, and proteins with lesser-known roles in CF, including apolipoproteins. Differentially abundant bacterial peptides were identified from known CF pathogens (e.g., Pseudomonas), as well as other taxa with potentially novel roles in CF. We used this host-microbe peptide panel for targeted parallel-reaction monitoring validation, demonstrating for the first time an MS-based assay effective for quantifying host-microbe protein dynamics within BAL cells from individual CF patients. Our integrated bioinformatic and analytical workflow combining discovery, verification, and validation should prove useful for diverse studies to characterize microbial contributors in airway diseases. Furthermore, we describe a promising preliminary panel of differentially abundant microbe and host peptide sequences for further study as potential markers of host-microbe relationships in CF disease pathogenesis.IMPORTANCEIdentifying microbial pathogenic contributors and dysregulated human responses in airway disease, such as CF, is critical to understanding disease progression and developing more effective treatments. To this end, characterizing the proteins expressed from bacterial microbes and human host cells during disease progression can provide valuable new insights. We describe here a new method to confidently detect and monitor abundance changes of both microbe and host proteins from challenging BAL samples commonly collected from CF patients. Our method uses both state-of-the art mass spectrometry-based instrumentation to detect proteins present in these samples and customized bioinformatic software tools to analyze the data and characterize detected proteins and their association with CF. We demonstrate the use of this method to characterize microbe and host proteins from individual BAL samples, paving the way for a new approach to understand molecular contributors to CF and other diseases of the airway.

Parallel accumulation‐serial fragmentation method for in‐depth proteomic analysis of bronchoalveolar lavage fluid collected from patients with nonsmall cell lung cancer

[Use of Laser Capture Microdissection and Surface-Enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Differential Proteins in Lung Adenocarcinoma and Lung Squamous Carcinoma].

Proteomic Analysis of the Air-Way Fluid in Lung Cancer. Detection of Periostin in Bronchoalveolar Lavage (BAL)

Large-scale, ion-current-based proteomics investigation of bronchoalveolar lavage fluid in chronic obstructive pulmonary disease patients.

An integrated metaproteomics workflow for studying host-microbe dynamics in bronchoalveolar lavage samples applied to cystic fibrosis disease

Abstract 4463: Tumor-derived Cell-Free DNA from Bronchoalveolar Lavage Fluid (BALF): A Potential Liquid Biopsy Analysis in Lung Cancer Patients

Bronchoalveolar Lavage As Potential Diagnostic Specimens to Genetic Testing in Advanced Nonsmall Cell Lung Cancer.

Application of Next Generation Sequencing in Pleural Effusion Molecular Profiling Using Oncomine™ Lung Cell-Free Total Nucleic Acid Research Assay.

Assessment of a high-throughput mass spectrometry method to accelerate biomarker discovery in clinical cancer cohorts using volumetric absorptive microsampling (VAMS) devices.

Bronchoalveolar Lavage Fluid-Isolated Biomarkers for the Diagnostic and Prognostic Assessment of Lung Cancer

High-throughput proteomic and phosphoproteomic analysis of formalin-fixed paraffin-embedded tissue

A rapid liquid biopsy of lung cancer by separation and detection of exfoliated tumor cells from bronchoal-veolar lavage fluid with a dual-layer "PERFECT" filter system

Relative Protein Quantification and Accessible Biology in Lung Tumor Proteomes from Four LC-MS/MS Discovery Platforms

Capture, Enrichment, and Mass Spectrometric Detection of Low-Molecular-Weight Biomarkers with Nanoporous Silicon Microparticles

Comparative Proteomic Analysis of Non-small-cell Lung Cancer and Normal Controls Using Serum Label-Free Quantitative Shotgun Technology

Proteomic analysis enables distinction of early- versus advanced-stage lung adenocarcinomas

Bronchoalveolar Lavage As a Potential Diagnostic Specimens to Genetic Testing in Advanced Lung Cancer

Proteomic profiling of bronchoalveolar lavage fluid in children with chronic pulmonary aspiration

Accelerated Protein Biomarker Discovery from FFPE Tissue Samples Using Single-Shot, Short Gradient Microflow SWATH MS

LC-MS/MS-Based Quantitative Proteomics Analysis of Different Stages of Non-Small-Cell Lung Cancer.

Investigating the use of novel blood processing methods to boost the identification of biomarkers of non-small cell lung cancer